Development of PD3 and PD3-B for PDEδ inhibition to modulate KRAS activity

References

• Cox AD, Fesik SW, Kimmelman AC, et al. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov 2014;13:1656–51.
   Web of Science ®Google Scholar
• Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci 2016;129:1287–92.
   PubMed Web of Science ®Google Scholar
• Gibbs JB, Sigal IS, Poe M, Scolnick EM. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A 1984;81:5704–8.
   PubMed Web of Science ®Google Scholar
• Scheffzek K, Ahmadian MR, Kabsch W, et al. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997;277:333–8.
   PubMed Web of Science ®Google Scholar
• Papke B, Der CJ. Drugging RAS: Know the enemy. Science 2017;355:1158–63.
   PubMed Web of Science ®Google Scholar
• Lanman BA, Allen JR, Allen JG, et al. Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors. J Med Chem 2020;63:52–65.
   PubMed Web of Science ®Google Scholar
• Fell JB, Fischer JP, Baer BR, et al. Identification of the clinical development candidate MRTX849, a covalent KRASG12C inhibitor for the treatment of cancer. J Med Chem 2020;63:6679–93.
   PubMed Web of Science ®Google Scholar
• Molina-Arcas M, Samani A, Downward J. Drugging the undruggable: advances on RAS targeting in cancer. Genes (Basel) 2021;12:899.
   PubMed Web of Science ®Google Scholar
• Ryan MB, Corcoran RB. Therapeutic strategies to target RAS-mutant cancers. Nat Rev Clin Oncol 2018;15:709–20.
   PubMed Web of Science ®Google Scholar
• Berndt N, Hamilton AD, Sebti SM. Targeting protein prenylation for cancer therapy. Nat Rev Cancer 2011;11:775–91.
   PubMed Web of Science ®Google Scholar
• Li N, Florio SK, Pettenati MJ, et al. Characterization of human and mouse rod cGMP phosphodiesterase delta subunit (PDE6D) and chromosomal localization of the human gene. Genomics 1998;49:76–82.
   PubMed Web of Science ®Google Scholar
• Watzlich D, Vetter I, Gotthardt K, et al. The interplay between RPGR, PDEδ and Arl2/3 regulate the ciliary targeting of farnesylated cargo. Embo Rep 2013;14:465–72.
   PubMed Web of Science ®Google Scholar
• Nancy V, Callebaut I, El Marjou A, de Gunzburg J. The delta subunit of retinal rod cGMP phosphodiesterase regulates the membrane association of Ras and Rap GTPases. J Biol Chem 2002;277:15076–84.
   PubMed Web of Science ®Google Scholar
• Baehr W. Membrane protein transport in photoreceptors: the function of PDEδ: the proctor lecture. Invest Ophthalmol Vis Sci 2014;55:8653–66.
   PubMed Web of Science ®Google Scholar
• Hanzal-Bayer M, Renault L, Roversi P, et al. The complex of Arl2-GTP and PDE delta: from structure to function. Embo J 2002;21:2095–106.
   PubMed Web of Science ®Google Scholar
• Linari M, Hanzal-Bayer M, Becker J. The delta subunit of rod specific cyclic GMP phosphodiesterase, PDE delta, interacts with the Arf-like protein Arl3 in a GTP specific manner. Febs Lett 1999;458:55–9.
   PubMed Web of Science ®Google Scholar
• Ismail SA, Chen YX, Rusinova A, et al. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nat Chem Biol 2011;7:942–9.
   PubMed Web of Science ®Google Scholar
• Weise K, Kapoor S, Werkmuller A, et al. Dissociation of the K-Ras4B/PDEδ complex upon contact with lipid membranes: membrane delivery instead of extraction. J Am Chem Soc 2012;134:11503–10.
   PubMed Web of Science ®Google Scholar
• Chandra A, Grecco HE, Pisupati V, et al. The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat Cell Biol 2011;14:148–58.
   PubMed Web of Science ®Google Scholar
• Schmick M, Vartak N, Papke B, et al. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell 2014;157:459–71.
   PubMed Web of Science ®Google Scholar
• Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013;497:638–42.
   PubMed Web of Science ®Google Scholar
• Zimmermann G, Schultz-Fademrecht C, Kuchler P, et al. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site. J Med Chem 2014;57:5435–48.
   PubMedGoogle Scholar
• Papke B, Murarka S, Vogel HA, et al. Identification of pyrazolopyridazinones as PDEδ inhibitors. Nat Commun 2016;7:11360.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhuang C, Chen L, et al. Structural biology-inspired discovery of novel KRAS-PDEδ inhibitors. J Med Chem 2017;60:9400–6.
   PubMedGoogle Scholar
• Martin-Gago P, Fansa EK, Klein CH, et al. A PDE6delta-KRas inhibitor chemotype with up to seven H-bonds and picomolar affinity that prevents efficient inhibitor release by Arl2. Angew Chem Int Ed Engl 2017;56:2423–8.
   PubMed Web of Science ®Google Scholar
• Leung EL, Luo LX, Li Y, Liu ZQ, et al. Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer. Int J Cancer 2019;145:1334–45.
   PubMed Web of Science ®Google Scholar
• Siddiqui FA, Alam C, Rosenqvist P, et al. PDE6D inhibitors with a new design principle selectively block K-Ras activity. ACS Omega 2020;5:832–42.
   PubMed Web of Science ®Google Scholar
• Dong G, Chen L, Zhang J, et al. Discovery of turn-on fluorescent probes for detecting PDEδ protein in living cells and tumor slices. Anal Chem 2020;92:9516–22.
   PubMed Web of Science ®Google Scholar
• Dong H, Claffey KP, Brocke S, Epstein PM. Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells. Springerplus 2013;2:680.
   PubMedGoogle Scholar
• Klein CH, Truxius DC, Vogel HA, et al. PDEδ inhibition impedes the proliferation and survival of human colorectal cancer cell lines harboring oncogenic KRas. Int J Cancer 2019;144:767–76.
   PubMed Web of Science ®Google Scholar
• Dietrich P, Hellerbrand C, Bosserhoff A. The delta subunit of rod-specific photoreceptor cGMP phosphodiesterase (PDE6D) contributes to hepatocellular carcinoma progression. Cancers (Basel) 2019;11:398.
   PubMed Web of Science ®Google Scholar
• Park S, Kwon DI, Lee J, Kim I. When indolizine meets quinoline: diversity-oriented synthesis of new polyheterocycles and their optical properties. ACS Comb Sci 2015;17:459–69.
   PubMed Web of Science ®Google Scholar
• Kwon S, Lee Y, Jung Y, et al. Mitochondria-targeting indolizino[3,2-c]quinolines as novel class of photosensitizers for photodynamic anticancer activity. Eur J Med Chem 2018;148:116–27.
   PubMed Web of Science ®Google Scholar
• Lim B, Baek B, Jang K, et al. Novel turn-on fluorescent biosensors for selective detection of cellular Fe3+ in lysosomes: thiophene as a selectivity-tuning handle for Fe3+ sensors. Dyes Pigments 2019;169:51–9.
   Web of Science ®Google Scholar
• Park J, Lim B, Lee NK, et al. Dual-functioning IQ-LVs as lysosomal viscosity probes with red-shifted emission and inhibitors of autophagic flux. Sens Actuat B Chem 2020;309:127764.
   Web of Science ®Google Scholar
• Park J, Lee JH, Lim B, et al. Fine tuning of the HOMO–LUMO gap of 6-(thiophen-2-yl) indolizino[3,2-c]quinolines and their self-assembly to form fluorescent organic nanoparticles: rational design and theoretical calculations. ChemPhotoChem 2021;5:58–67.
   Web of Science ®Google Scholar
• Lea WA, Simeonov A. Fluorescence polarization assays in small molecule screening. Expert Opin Drug Discov 2011;6:17–32.
   PubMed Web of Science ®Google Scholar